Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB204
- Development stage
- Unknown
- Lead developer
- Ligand Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
SB204 is a first-in-class topical nitric oxide-releasing drug candidate developed by Novan, Inc. for the treatment of acne vulgaris. The product utilizes Novan's proprietary Nitricil technology, which consists of nitric oxide-releasing silica nanoparticles. Upon application, the gel releases nitric oxide, which exerts a multi-pronged therapeutic effect: it acts as an antimicrobial agent against *Cutibacterium acnes*, reduces the production of sebum by sebocytes, and inhibits the NLRP3 inflammasome to provide anti-inflammatory benefits. In 2017, Novan reported results from two pivotal Phase 3 clinical trials (NI-AC301 and NI-AC302); while the drug demonstrated statistical significance in one trial, it failed to meet primary endpoints in the second, leading to the discontinuation of its development for acne.
- Other names
- SB204 4% gelNitric oxide-releasing gel
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on SB204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB204.